Polymorphism of cytochrome P450 and xenobiotic toxicity

Toxicology

Volumn 181-182, Issue , 2002, Pages 447-452

  Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cytochrome P450; Polymorphism; Xenobiotic toxicity

Indexed keywords

CYTOCHROME P450; XENOBIOTIC AGENT;

ALLELE; ARTICLE; CANCER RISK; DRUG EFFICACY; DRUG METABOLISM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TOXICOLOGY; XENOBIOTIC METABOLISM;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOENZYMES; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC; XENOBIOTICS;

EID: 0037184794     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(02)00492-4     Document Type: Article

References (13)

1. Bertz R.J., Granneman G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32:1997;210-258.
2. Evans W.E., Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 286:1999;487-491.
3. Eiselt R., Domanski T.L., Zibat A., Mueller R., Presecan-Siedel E., Hustert E., Zanger U.M., Brockmoller J., Klenk H.P., Meyer U.A., Khan K.K., He Y.A., Halpert J.R., Wojnowski L. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics. 11:2001;447-458.
4. Fukuda T., Nishida Y., Imaoka S., Hiroi T., Naohara M., Funae Y., Azuma J. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Arch. Biochem. Biophys. 380:2000;303-308.
5. Ingelman-Sundberg M., Daly A.K., Oscarson M., Nebert D.W. Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles. Pharmacogenetics. 10:2000;91-93.
6. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J. Intern. Med. 250:2001;186-200.
7. Johansson I., Lundqvist E., Bertilsson L., Dahl M.L., Sjoqvist F., Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA. 90:1993;11 825-11 829.
8. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., Watkins P.B., Daly A., Wrighton S.A., Hall S.D., Maurel P., Relling M., Brimer C., Yasuda K., Venkataramanan R., Strom S., Thummel K., Boguski M.S., Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27:2001;383-391.
9. Oscarson M., Hidestrand M., Johansson I., Ingelman-Sundberg M. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol. Pharmacol. 52:1997;1034-1040.
10. Oscarson M. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab. Dispos. 29:2001;91-95.
11. Rao Y., Hoffmann E., Zia M., Bodin L., Zeman M., Sellers E.M., Tyndale R.F. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol. Pharmacol. 58:2000;747-755.
12. Rylander T., Neve E.P.A., Ingelman-Sundberg M., Oscarson M. Identification and tissue distribution of the novel human cytochrome P450 2S1 (CYP2S1). Biochem. Biophys. Res. Commun. 281:2001;529-535.
13. Ingelman-Sundberg M., Oscarson M., McLellan R.A. Polymorphic human cytochrome P450 enzymes: an opportunity for invidualised drug treatment. Trends Pharmacol. Sci. 20:1999;342-349.